Cargando…

SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody

OBJECTIVE: To determine whether an SRC homology 2 domain-containing phosphotyrosine phosphatase 2 (SHP2) inhibitor would increase muscle-specific kinase (MuSK) phosphorylation and override the inhibitory effect of MuSK-antibodies (Abs). METHODS: The effect of the SHP2 inhibitor NSC-87877 on MuSK pho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huda, Saif, Cao, Michelangelo, De Rosa, Anna, Woodhall, Mark, Rodriguez Cruz, Pedro M., Cossins, Judith, Maestri, Michelangelo, Ricciardi, Roberta, Evoli, Amelia, Beeson, David, Vincent, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935836/ https://www.ncbi.nlm.nih.gov/pubmed/31831571 http://dx.doi.org/10.1212/NXI.0000000000000645

Ejemplares similares

IgG1-3 MuSK Antibodies Inhibit AChR Cluster Formation, Restored by SHP2 Inhibitor, Despite Normal MuSK, DOK7, or AChR Subunit Phosphorylation
por: Cao, Michelangelo, et al.
Publicado: (2023)

Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
por: Spagni, Gregorio, et al.
Publicado: (2022)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK
por: Yilmaz, Vuslat, et al.
Publicado: (2015)

Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis
por: Lee, Jae‐Yun, et al.
Publicado: (2016)

Plasma Myokine Profiles in Patients With AChR- and MuSK-Ab-Positive Myasthenia Gravis
por: Seok, Jo Woon, et al.
Publicado: (2023)

MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters
por: Koneczny, Inga, et al.
Publicado: (2013)

Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis
por: Bastakoti, Sanjiv, et al.
Publicado: (2021)

Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs
por: Cetin, Hakan, et al.
Publicado: (2020)

Juvenile Generalized Myasthenia Gravis With AChR and MuSK Antibody Double Positivity: A Case Report With a Review of the Literature
por: Ge, XiuShan, et al.
Publicado: (2022)

IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG
por: Huda, Saif, et al.
Publicado: (2017)

MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine
por: Bhaskar, Shalini, et al.
Publicado: (2022)

Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis
por: Kwon, Young Nam, et al.
Publicado: (2022)

MuSK-Associated Myasthenia Gravis: Clinical Features and Management
por: Rodolico, Carmelo, et al.
Publicado: (2020)

MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity
por: Huijbers, Maartje G., et al.
Publicado: (2019)

Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis
por: Kim, Seung Woo, et al.
Publicado: (2017)

Protein Tyrosine Phosphatase Receptor Type R (PTPRR) Reduces AChR Clustering by Dephosphorylating MuSK
por: Chen, Yanxun, et al.
Publicado: (2022)

Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China
por: Zhang, Zunwei, et al.
Publicado: (2020)

Myasthenia gravis: MuSK MG, late-onset MG and ocular MG
por: Deymeer, Feza
Publicado: (2020)

Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes
por: Huang, Qi, et al.
Publicado: (2022)

Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis
por: Marino, Mariapaola, et al.
Publicado: (2020)

Anti-MuSK-Positive Myasthenia Gravis in a Patient with Parkinsonism and Cognitive Impairment
por: Lanfranconi, S., et al.
Publicado: (2011)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
por: Schneider-Gold, Christiane, et al.
Publicado: (2017)

The impact of rituximab infusion protocol on the long‐term outcome in anti‐MuSK myasthenia gravis
por: Cortés‐Vicente, Elena, et al.
Publicado: (2018)

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis
por: Vergoossen, Dana L. E., et al.
Publicado: (2021)

Anti-MuSK Positive Myasthenia Gravis with Anti-Lrp4 and Anti-titin Antibodies
por: Yamashita, Rika, et al.
Publicado: (2020)

Is paravertebral muscles edema a consequence of neurogenic changes in MuSK-positive myasthenia gravis?
por: Bardakov, Sergey N., et al.
Publicado: (2022)

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
por: Vakrakou, Aigli G., et al.
Publicado: (2023)

Laboratory Investigation of Hybrid IgG4 k/λ in MuSK Positive Myasthenia Gravis
por: Basile, Umberto, et al.
Publicado: (2021)

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
por: Zhao, Rui, et al.
Publicado: (2021)

Effects of the ß2-Adrenoceptor Agonist, Albuterol, in a Mouse Model of Anti-MuSK Myasthenia Gravis
por: Ghazanfari, Nazanin, et al.
Publicado: (2014)

Grave Prognosis of the MuscleSpecific Kinase (MuSK)-positive Myasthenia Gravis (MG): A False Prejudice
por: Hiew, Fu Liong
Publicado: (2020)

Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study
por: Meng, Xin, et al.
Publicado: (2022)

A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis
por: Cai, Yu, et al.
Publicado: (2021)

Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure
por: Rodríguez Cruz, Pedro M., et al.
Publicado: (2019)

Clinical and Electrophysiologic Responses to Acetylcholinesterase Inhibitors in MuSK-Antibody-Positive Myasthenia Gravis: Evidence for Cholinergic Neuromuscular Hyperactivity
por: Shin, Ha Young, et al.
Publicado: (2014)

Altered Active Zones, Vesicle Pools, Nerve Terminal Conductivity, and Morphology during Experimental MuSK Myasthenia Gravis
por: Patel, Vishwendra, et al.
Publicado: (2014)

Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated with Outpatient Periodic Weekly Blood Purification Therapy
por: Deguchi, Kentaro, et al.
Publicado: (2018)

Clinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China
por: Zhou, Yufan, et al.
Publicado: (2022)

Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
por: Kordas, Gregory, et al.
Publicado: (2014)

The Clinical Outcome in AChR-Positive Generalized Myasthenia Gravis: A Retrospective Observational Study
por: Ojha, Pawan T., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mijgmmaard5ffl4v4al593t986